A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have completed the last visit of an eligible study period of originating study
Participants must be willing to follow the birth control measures during and after study treatment if woman of childbearing potential
Participants Must Not:
Participants must not have an unstable or uncontrolled illness, including but not limited to a cerebro-cardiovascular, respiratory, liver, kidney, gastrointestinal, endocrine, blood, or neurologic disease or abnormal lab results, that the study investigator thinks makes it unsafe or inappropriate for the participant to participate in this study
Participants must not have stopped taking mirikizumab during a previous study if the study investigator does not think the participant should resume taking mirikizumab
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo